Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

GLP-1 drugs are reshaping how people eat, but the food industry is lagging behind. This op-ed explores the growing nutrient ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Discover a study exploring how GLP-1 receptor agonists may reduce symptoms of hidradenitis suppurativa through weight loss and anti-inflammatory effects.

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The ...

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted predominantly by intestinal enteroendocrine L cells in response to nutrient ingestion. By enhancing insulin secretion, delaying ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

The intricate interplay between pancreatic beta cells and glucagon-like peptide-1 (GLP-1) has drawn considerable attention in efforts to improve the diagnosis and treatment of diabetes and ...

Tennis legend Serena Williams has sparked conversations around fitness and health after reports of her weight loss journey ...